Logo Logo Logo Logo Logo
  • About Us
    • About Odylia
    • Our Board
    • Our Team
    • Our Partners
  • Our Impact
    • reImagine
    • Our Mission
    • Get Involved
    • News
    • Rare Disease Day
  • Research & Services
    • Services Overview
    • Gene Therapy Pipeline
    • Brydge Solutions
    • Anc80 Resources
  • Resources
    • Rare Disease Resources
    • Fundraising Resources
    • Webinars and Presentations
    • Newsletter
  • Donate
  • About Us
    • About Odylia
    • Our Board
    • Our Team
    • Our Partners
  • Our Impact
    • reImagine
    • Our Mission
    • Get Involved
    • News
    • Rare Disease Day
  • Research & Services
    • Services Overview
    • Gene Therapy Pipeline
    • Brydge Solutions
    • Anc80 Resources
  • Resources
    • Rare Disease Resources
    • Fundraising Resources
    • Webinars and Presentations
    • Newsletter
  • Donate
Services
  • Services Overview
  • Brydge Solutions

Visit Odylia's linked in page Visit Odylia's linked in page

Science
  • Research and Development
  • Our Mission
Resources
  • Resources
  • Webinars and Presentations
  • Clinical Trials
Latest News
  • Odylia Announces Promotion of Ashley Winslow to President and Chief Scientific Officer
  • Odylia to Host an Update on the RPGRIP1 Gene Therapy Program and Plans for 2022, Feb 3rd
  • Odylia Therapeutics Granted Orphan Drug and Rare Pediatric Disease Designations by the FDA for OT-004, an Investigational Gene Therapy for RPGRIP1- associated Retinal Dystrophies
Odylia Therapeutics logo

© 2022 Odylia Therapeutics | Registered 501(c)(3). EIN: 82-2120760 | Site by Hester Designs